Intermountain Program on Antibiotic Resistance and microbial Threats (IMPART)

抗生素耐药性和微生物威胁山间计划 (IMPART)

• 批准号: 10646169
• 负责人: MICHAEL A. RUBIN
• 金额: $ 73.72万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-01 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10646169
• 关键词: Intermountain; Program; Antibiotic; Resistance; microbial

PROJECT SUMMARY We enthusiastically propose to renew our CDC Prevention Epicenter, entitled “InterMountain Program in Antibiotic Resistance and microbial Threats (IMPART). Our proposal assembles an exceptional group of investigators who have an extraordinary capacity to conduct large-scale observational studies, as well as lead or co-lead interventional studies that range in scope from small pilots to multi-community randomized trials The University of Utah is the hub for our program, with Intermountain Health, a large regional integrated health system, serving as a major node. The Veterans Affairs (VA) Salt Lake City Healthcare System is another key partner for our Prevention Epicenter site, operating within a programmatic network that encompasses the entire VA health system. The resources that we bring to the CDC Prevention Epicenter Program will be broadly beneficial to its mission to improve healthcare safety and prevent healthcare-associated infection. We have accumulated the experience in translational research and expertise in multi-disciplinary methods to make significant contributions to improve the quality of antibiotic use, combat antibiotic resistance, and enhance health system response to microbial threats across the continuum of care. Moreover, we have developed a computational environment to support comprehensive epidemiological analysis of infections within the Department of Veterans Affairs (VA) Health System, as well as Intermountain Healthcare and University of Utah Health (UHealth). Our proposed research has a high level of significance for policy-making and implementation. Core Project 1 evaluates alternative implementation strategies for outpatient stewardship and advances dissemination of best practices for AS. Core Project 2 tackles a longstanding source of controversy in the healthcare epidemiology community, namely, the role of active surveillance and contact precautions (CP) in preventing healthcare-associated infection due to endemic multi-drug resistant organisms (MDRO) such as methicillin-resistant Staphylococcus aureus (MRSA). A period of partial CP deimplementation in some VA facilities, triggered in response to the emergence of COVID-19, creates the opportunity to study the impact of this natural experiment. Core Project 3 links an epidemiological analysis of transmission pathways in LTC facilities to the development and implementation of novel approaches to improve practice. Core Project 4 confronts the global health challenge of COVID-19, to enhance preparedness for future epidemics and increase understanding of how to control healthcare spread of both seasonal and novel viruses. We are committed to active engagement with other Prevention Epicenter sites on collaborative projects and to work closely with public health entities at national, state, and local levels. We also pledge to contribute to programmatic domains and pathogen-specific workgroups set up under the auspices of the Prevention Epicenter Program. For all of our activities, close alignment with the health priorities of CDC will be established, along with substantial programmatic involvement of CDC staff.

项目摘要 我们热情地建议更新我们的疾病预防控制中心预防中心，题为“山区间计划， 抗生素耐药性和微生物威胁（IMPART）。我们的提议召集了一个特殊的小组， 研究人员具有进行大规模观察性研究的非凡能力， 或共同领导的干预性研究，范围从小型试点到多社区随机试验。 犹他州大学是我们项目的中心，与山间健康，一个大型的区域综合健康 系统，作为主要节点。退伍军人事务部（VA）湖城医疗保健系统是另一个关键 我们的预防中心网站的合作伙伴，在一个包括 整个卫生系统。我们为疾病预防控制中心预防中心计划带来的资源将广泛 有利于其提高医疗保健安全性和预防医疗保健相关感染的使命。我们有 积累了翻译研究的经验和多学科方法的专业知识， 为提高抗生素使用质量、对抗抗生素耐药性和增强 卫生系统应对整个护理过程中的微生物威胁。此外，我们还开发了一个 计算环境，以支持对艾滋病毒/艾滋病感染进行全面的流行病学分析， 退伍军人事务部（VA）卫生系统，以及山间医疗保健和大学 犹他州卫生部。我们提出的研究对政策制定具有高度的意义， 实施.核心项目1评估门诊管理的替代实施策略， 促进AS最佳实践的传播。核心项目2解决了长期存在的争议 在卫生保健流行病学界，即积极监测和接触预防措施的作用 (CP)预防由地方性多重耐药微生物（MDRO）引起的医疗保健相关感染 如耐甲氧西林金黄色葡萄球菌（MRSA）。一些国家部分取消CP的时期 为应对COVID-19的出现而启动的VA设施，为研究其影响创造了机会 这一自然实验。核心项目3将LTC传播途径的流行病学分析联系起来 设施，以开发和实施新的方法，以改善实践。核心项目4 应对COVID-19的全球健康挑战，加强对未来流行病的准备， 提高对如何控制季节性和新型病毒在医疗保健中传播的认识。我们 致力于积极参与其他预防中心的合作项目， 与国家、州和地方各级的公共卫生实体密切合作。我们还承诺， 在预防艾滋病毒/艾滋病方案主持下设立的方案领域和病原体特异性工作组 震中计划。对于我们所有的活动，与疾病预防控制中心的卫生优先事项密切配合， 沿着疾病预防控制中心工作人员的大量方案参与。